Evidence map›Paper›PMID 36771111›Full record

ReviewMolecules (Basel, Switzerland)2023

Co-Encapsulation of Drugs for Topical Application-A Review.

Janaína Artem Ataide, Julia Cedran Coco, Érica Mendes Dos Santos, Viviane Beraldo-Araujo, Jéssica Ribeiro Alves Silva, Karine Cappuccio de Castro, André Moreni Lopes, Nina Filipczak, Satya Siva Kishan Yalamarty, Vladimir P Torchilin and 1 more

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Janaína Artem AtaideFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-1929-9474
Julia Cedran CocoFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-8495-0796
Érica Mendes Dos SantosFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-0686-6679
Viviane Beraldo-AraujoFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-6868-5208
Jéssica Ribeiro Alves SilvaFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.
Karine Cappuccio de CastroFaculty of Chemical Engineering, University of Campinas (UNICAMP), Campinas 13083-852, SP, Brazil.ORCID 0000-0001-9782-4767
André Moreni LopesFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-3570-2470
Nina FilipczakCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0001-9285-8298
Satya Siva Kishan YalamartyCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0002-2941-0754
Vladimir P TorchilinCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.
Priscila Gava MazzolaFaculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-3795-8189

Funding

São Paulo Research Foundation 2018/06475-4, 2021/12452-0, 2018/07707-6, 2017/10789-1, 2018/10799-0; 2021/00319-3; 2020/11333-4
6 · The paper itself

Abstract

Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients' lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents' applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.

Indexed as

NanoparticlesSkin DiseasesAdministration, CutaneousAdministration, TopicalDrug CarriersDrug Delivery SystemsHumansPharmaceutical PreparationsSkinSkin AbsorptionDrug CarriersPharmaceutical Preparationsco-encapsulationnanoparticlesskin barriertopical delivery

Identifiers

PMID36771111
PMCPMC9921006

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.